Investors Urged to Join Class Action Against Aquestive Therapeutics Over Stock Price Drop

Investors Warned of Possible Class Action Against Aquestive Therapeutics

Investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) have been alerted by The Gross Law Firm regarding the potential for a class action lawsuit following a steep decline in the company’s stock price. Those who purchased shares during the specified class period from June 16, 2025, to January 8, 2026, are encouraged to participate, particularly those who suffered losses. Significantly, their involvement could lead them to become lead plaintiffs, although this is not mandatory for seeking recovery.

Recent Developments and Allegations

The issues surrounding Aquestive center largely on claims made by the company regarding its New Drug Application (NDA) for Anaphylm, a potential treatment for severe allergic reactions. As per the allegations, the defendants reportedly provided the investors with overly optimistic statements while failing to disclose critical information regarding the NDA’s review status. Specifically, the complaint points out that important factors concerning the product’s usability had been misrepresented or concealed, misleading investors about the company’s standing before the FDA.

On January 9, 2026, Aquestive disclosed that they received a letter from the FDA outlining several deficiencies. This letter highlighted significant issues that blocked any progress toward labeling discussions for Anaphylm, indicating that the approval process was still ongoing. This announcement, which confirmed delays past the anticipated Prescription Drug User Fee Act date of January 31, 2026, led to a dramatic fallout for the company’s stock. The share price plummeted over 37%, from a closing price of $6.21 on January 8, 2026, to just $3.91 the following day.

Importance for Shareholders

With May 4, 2026, marking the deadline for registering as a lead plaintiff, shareholders are urged to act promptly. Registering will also provide access to a portfolio monitoring tool allowing them to receive updates throughout the case’s progression. The law firm emphasizes that participating in this action will involve no financial obligation for the shareholders.

The Gross Law Firm, recognized nationally for its dedication to protecting the rights of investors, states that it is committed to pursuing justice for those who have experienced losses due to corporate malfeasance and misleading business practices. This firm routinely advocates for ethical standards in corporate behavior, seeking reparations for stakeholders who find themselves misled.

Next Steps for Interested Investors

Shareholders looking to become part of this class action can reach out via the links provided by The Gross Law Firm. The firm has established a streamlined process for interested parties to submit their information, ensuring they remain informed of all developments related to this case.

In conclusion, the situation surrounding Aquestive Therapeutics presents a stark reminder of the risks inherent in investing, particularly in volatile markets influenced by regulatory processes. This class action not only offers a path for recovery for affected investors but also stands as a measure to promote corporate accountability within the pharmaceutical sector.

For those contemplating their investment strategies and considering the implications of this news, it may be prudent to consult with financial advisors to assess individual positions carefully. The investment landscape remains uncertain, and such legal actions highlight the importance of due diligence and complete transparency in corporate communications.